Correlation between p53, c-erbB-2, and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications

Journal of Pathology

Volumn 187, Issue 2, 1999, Pages 207-216

  Rudolph, Pierre ^a   Olsson, Håkan ^b   Bonatz, Gabriele ^a   Ratjen, Virgo ^a   Bolte, Hendrik ^a   Baldetorp, Bo ^b   Fernö, Mårten ^b   Parwaresch, Reza ^a   Alm, Per ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; c erbB 2; Ki 67; p53; Prognosis; Proliferation; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); KI 67 ANTIGEN; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P53; STEROID RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CELL DIVISION; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM PROTEINS; PLOIDIES; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032904256     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:2<207::AID-PATH223>3.0.CO;2-U     Document Type: Article

References (56)

1. Landberg G, Roos G. The cell cycle in breast cancer. APMIS 1997; 105: 575-589.
2. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, Dupont WD, Parl FF. p53 gene mutations and steroid receptor status in breast cancer. Clinicopathologic correlations and prognostic assessment. Cancer 1994; 73: 2147-2156.
3. Lizard-Nacol S, Riedinger JM, Lizard G, et al. Loss of heterozygosity at the TP53 gene: independent occurrence from genetic instability events in node-negative breast cancer. Int J Cancer 1997; 72: 599-603.
4. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-416.
5. Parwaresch R, Rudolph P. The cell cycle - theory and applications to cancer. Onkologie 1996; 19: 464-472.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
7. Slamon DJ. Studies of the HER-2/neu proto-oncogene in human breast cancer. Cancer Invest 1990; 8: 253.
8. Inglehart JD, Kraus MH, Langton BC, Huper G, Kerns BJ, Marks JR. Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 1990; 50: 6701-6707.
9. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991; 49: 650-655.
10. Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 1992; 10: 1044-1048.
11. Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study of 942 cases. Breast Cancer Res Treat 1995; 35: 283-291.
12. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1132-1139.
13. Schechter AL, Hung MC, Vaidyanathan L, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985; 229: 976-978.
14. Tsai Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci USA 1988; 85: 7177-7181.
15. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxanthrone sensitivity. Oncogene 1993; 8: 933-938.
16. Hellemans P, van Dam PA, Geyskens M, van Oosterom AT, Buytaert P, Van Marck E. Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast. J Clin Pathol 1995; 48: 147-150.
17. Isaacs RJ, Davies SL, Wells NJ, Harris AL. Topoisomerases II alpha and beta as therapy targets in breast cancer. Anticancer Drugs 1995; 6: 195-211.
18. Houlbrook S, Addison CM, Davies SL, et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 1995; 72: 1454-1461 (published erratum appears in Br J Cancer 1996; 74: 1154).
19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
20. Bacus SS, Zelnick CR, Plowman G, Yarden Y. Expression of the erbB-2 family of growth factor receptors and their ligands in breast cancers. Implication for tumor biology and clinical behavior. Am J Clin Pathol 1994; 102: S13-S24.
21. Kellner U, Heidelbrecht HJ, Rudolph P, et al. Detection of topoisomerase II alpha in cell lines and tissues - characterization of five novel monoclonal antibodies. J Histochem Cytochem 1997; 45: 251-263.
22. Rudolph P, Lappe T, Schubert C, Schmidt D, Parwaresch RM, Christophers E. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions. Am J Pathol 1995; 147: 1615-1625.
23. Heidebrecht HJ, Buck F, Haas K, Wacker HH, Parwaresch R. Monoclonal antibodies Ki-S3 and Ki-S5 yield new data on the 'Ki-67' proteins. Cell Prolif 1996; 29: 413-425.
24. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326: 1756-1761.
25. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
26. van Diest PJ, Baak JP, Matze Cok P, et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 1992; 23: 603-607.
27. Norgren A, Borg A, Ferno M, Johansson U, Lindahl B, Tsiobanelis K. Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer. Anticancer Res 1982; 2: 315-320.
28. Thornthwaite JT, Sugarbaker EV, Temple WJ. Preparation of tissues for DNA flow cytometric analysis. Cytometry 1980; 1: 229-237.
29. Lee GM, Thornthwaite JT, Rasch EM. Pictogram per cell determination of DNA by flow cytofluorometry. Anal Biochem 1984; 137: 221-226.
30. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359-2365.
31. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 1996; 69: 135-141.
32. Host H, Lund E. Age as a prognostic factor in breast cancer. Cancer 1986; 57: 2217-2221.
33. Sigurdsson H, Baldetorp B, Borg A, et al. Indicators of prognosis in node-negative breast cancer. N Engl J Med 1990; 322: 1045-1053.
34. Osborne CK. Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 1992; 10: 679-682.
35. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncoll 1995; 13: 821-830.
36. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - a review. Gene 1995; 159: 19-27.
37. Lane DP. Cancer: p53, guardian of the genome. Nature 1992; 358: 15-16.
38. Walker RA, Lees E, Webb MB, Hearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer 1996; 74: 1796-1800.
39. Sandri MI, Isaacs RJ, Ongkeko WM, et al. p53 regulates the minimal promoter of the human topoisomerase II alpha gene. Nucleic Acids Res 1996; 24: 4464-4470.
40. Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD. p53 and c-erbB-2 protein expression in breast carcinomas An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992; 98: 408-418.
41. Sirvent JJ, Salvado MT, Santafe M, et al. p53 in breast cancer. Its relation to histological grade, lymph-node status, hormone receptors, cell-proliferation fraction (Ki-67) and c-erbB-2. Immunohistochemical study of 153 cases. Histol Histopathol 1995; 10: 531-539.
42. Ro JS, el-Naggar A, Ro JY, et al. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 1989; 49: 6941-6944.
43. Allred DC, Clark GM, Molina R, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 974-979.
44. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10: 2435-2446.
45. O'Reilly SM, Camplejohn RS, Barnes DM, et al. DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer 1990; 61: 671-674.
46. Aubele M, Auer G, Falkmer U, et al. Identification of a low-risk group of stage I breast cancer patients by cytometrically assessed DNA and nuclear texture parameters, J Pathol 1995; 177: 377-384.
47. Watatani M, Nagayama K, Imanishi Y, et al. Genetic alterations on chromosome 17 in human breast cancer: relationships to clinical features and DNA ploidy. Breast Cancer Res Treat 1993; 28: 231-239.
48. Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer [In Process Citation]. Hum Pathol 1997; 28: 1180-1188.
49. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase 11 in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209-214.
50. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989; 7: 1120-1128.
51. Muss HB, Thor AD, Berry DA, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-1266.
52. Gaglia P, Bernardi A, Venesio T, et al. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 1993; 29A: 1509-1513.
53. Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M, Lampertico P. Proliferation index as a prognostic marker in breast cancer. Cancer 1993; 71: 3926-3931.
54. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 1996; 122: 687-692.
55. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 1995; 71: 146-149.
56. Baringa M. From bench top to bedside. Science 1997; 278: 1036-1039.